Alphatec Holdings, Inc. (NASDAQ:ATEC) Stock Position Raised by Emerald Mutual Fund Advisers Trust

Emerald Mutual Fund Advisers Trust lifted its holdings in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 94.3% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 841,643 shares of the medical technology company's stock after purchasing an additional 408,516 shares during the quarter. Emerald Mutual Fund Advisers Trust owned about 0.59% of Alphatec worth $7,726,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Barclays PLC increased its stake in Alphatec by 362.3% during the third quarter. Barclays PLC now owns 170,546 shares of the medical technology company's stock worth $948,000 after acquiring an additional 133,653 shares during the last quarter. Invst LLC increased its position in Alphatec by 3.7% during the 3rd quarter. Invst LLC now owns 158,549 shares of the medical technology company's stock worth $882,000 after purchasing an additional 5,630 shares in the last quarter. Franklin Resources Inc. lifted its position in Alphatec by 299.3% during the third quarter. Franklin Resources Inc. now owns 64,450 shares of the medical technology company's stock valued at $343,000 after buying an additional 48,308 shares in the last quarter. Courier Capital LLC increased its position in shares of Alphatec by 76.9% in the fourth quarter. Courier Capital LLC now owns 69,000 shares of the medical technology company's stock worth $633,000 after acquiring an additional 30,000 shares in the last quarter. Finally, Ballentine Partners LLC purchased a new position in shares of Alphatec in the 4th quarter valued at $120,000. 66.35% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Alphatec

In other Alphatec news, EVP David Sponsel sold 33,732 shares of the company's stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $10.83, for a total value of $365,317.56. Following the completion of the transaction, the executive vice president now owns 668,977 shares in the company, valued at approximately $7,245,020.91. This represents a 4.80 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Patrick Miles sold 12,691 shares of Alphatec stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $10.64, for a total value of $135,032.24. Following the sale, the chief executive officer now directly owns 5,857,603 shares in the company, valued at approximately $62,324,895.92. This trade represents a 0.22 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 222,113 shares of company stock worth $2,519,725. 22.80% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research analysts have commented on the company. StockNews.com raised Alphatec from a "sell" rating to a "hold" rating in a research report on Friday, February 28th. Needham & Company LLC restated a "buy" rating and issued a $16.00 price target on shares of Alphatec in a report on Friday. Barclays increased their price objective on shares of Alphatec from $20.00 to $21.00 and gave the company an "overweight" rating in a research report on Wednesday, January 22nd. HC Wainwright reaffirmed a "buy" rating and set a $20.00 price target on shares of Alphatec in a research note on Monday, April 14th. Finally, Piper Sandler reiterated an "overweight" rating and issued a $15.00 price objective (up previously from $13.00) on shares of Alphatec in a report on Friday. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $17.89.

Alphatec Stock Performance

Shares of NASDAQ ATEC traded up $0.94 during trading on Friday, reaching $12.00. The stock had a trading volume of 4,701,141 shares, compared to its average volume of 2,074,909. The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.15 and a current ratio of 2.32. The stock has a market cap of $1.75 billion, a PE ratio of -9.38 and a beta of 1.20. Alphatec Holdings, Inc. has a one year low of $4.88 and a one year high of $13.79. The firm's 50 day moving average price is $10.46 and its two-hundred day moving average price is $9.92.

Alphatec (NASDAQ:ATEC - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical technology company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.23). Alphatec had a negative net margin of 31.06% and a negative return on equity of 541.39%. The business had revenue of $169.18 million for the quarter, compared to the consensus estimate of $167.57 million. During the same period in the prior year, the company earned ($0.34) EPS. Alphatec's quarterly revenue was up 22.2% on a year-over-year basis. On average, research analysts forecast that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.